Microbiological Appraisal of Levofloxacin Activity Against Pseudomonas aeruginosa Biofilm in Combination with Different Calcium Channel Blockers In Vitro

REFERENCES

• Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. An-timicrob Agents Chemother 2007; 51 (11): 4062–4070.
   PubMed Web of Science ®Google Scholar
• Huang SS, Lee SC, Lee N, See LC, Tsai MH, Shieh WB. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosoco-mial infections. J Microbiol Immunol Infect 2007; 40 (2): 134–140.
   PubMedGoogle Scholar
• Rogues AM, Dumartin C, Amadeo B, Venier AG, Marty N, Parneix P, et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007; 28 (12): 1389–1395.
   PubMed Web of Science ®Google Scholar
• Algun U, Arisoy A, Gunduz T, Ozbakkaloglu B. The resist-ance of Pseudomonas aeruginosa strains to fluoroquinolone group of antibiotics. Ind J Med Microbiol 2004; 22 (2): 112–114.
   PubMedGoogle Scholar
• Auckenthaler R, Michea-Hamzehpour M, Pechere JC. In-vitro activity of newer quinolones against aerobic bacteria. J An-timicrob Chemother 1986; 17 Suppl B: 29-39.
   Google Scholar
• DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dos-ing strategies of antibacterials utilizing pharmacodynamic princi-ples: Impact on the development of resistance. Drugs 2006; 66 (1): 1–14.
   PubMed Web of Science ®Google Scholar
• Morgan-Linnell SK, Zechiedrich L. Contributions of the combined effects of topoisomerase mutations toward fluoro-quinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2007; 51 (11): 4205–4208.
   PubMed Web of Science ®Google Scholar
• Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003; 112 (10): 1466–1477.
   PubMed Web of Science ®Google Scholar
• Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: From the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2 (2): 95–108.
   PubMed Web of Science ®Google Scholar
• Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4 (Suppl 2): 49–54.
   PubMedGoogle Scholar
• Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options. Pharmacotherapy 2005; 25 (10): 1353–1364.
   PubMed Web of Science ®Google Scholar
• Riedinger JL, Robbins U. Prevention of latrogenic illness: Adverse drug reactions and nosocomial infections in hospitalized older adults. Clin Geriatr Med 1998; 14 (4): 681–698.
   PubMed Web of Science ®Google Scholar
• Kumar KA, Ganguly K, Mazumdar K, Dutta NK, Dastidar SG, Chakrabarty AN. Amlodipine: A cardiovascular drug with powerful antimicrobial property. Acta Microbiol Pol 2003; 52 (3): 285–292.
   PubMedGoogle Scholar
• Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13 (1): 34–40.
   PubMed Web of Science ®Google Scholar
• Hall-Stoodley L, Stoodley P. Biofilm formation and dis-persal and the transmission of human pathogens. Trends Micro-biol 2005; 13 (1): 7–10.
   PubMed Web of Science ®Google Scholar
• Mah T, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 11/20426 (6964): 306–310.
   Web of Science ®Google Scholar
• Palmer RJ,Jr, Stoodley P. Biofilms 2007: Broadened hori-zons and new emphases. J Bacteriol 2007; 189 (22): 7948–7960.
   PubMed Web of Science ®Google Scholar
• Romero M, Sanchez I, Pujol MD. New advances in the field of calcium channel antagonists: Cardiovascular effects and structure-activity relationships. Curr Med Chem - Cardiovasc Hematol Agents 2003; 61 (2): 113–141.
   Google Scholar
• Budriesi R, Cosimelli B, loan P, Carosati E, Ugenti MP, Spisani R. Diltiazem analogues: The last ten years on structure activity relationships. Curr Med Chem 2007; 14 (3): 279–287.
   Google Scholar
• Massingham R, Van Zwieten PA. Bepridil: A pharmaco-logical reappraisal of its potential beneficial effects in angina and tissue protection following ischemia. Cardiovasc Drugs Ther 1989; 3 (5): 731–742.
   PubMed Web of Science ®Google Scholar
• Hollingshead LM, Faulds D, Fitton A. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs 1992; 44 (5): 835–857.
   PubMed Web of Science ®Google Scholar
• Gunics G, Motohashi N, Amaral L, Farkas S, Molnar J. Interaction between antibiotics and non-conventional antibiotics on bacteria. Int J Antimicrob Agents 2000; 14 (3): 239–242.
   PubMed Web of Science ®Google Scholar
• Cohn RC, Rudzienski L, Putnam RW. Verapamil-to-bramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro. Chemotherapy 1995; 41 (5): 330–333.
   PubMed Web of Science ®Google Scholar
• Asok Kumar K, Mazumdar K, Dutta NK, Karak P, Dasti-dar SG, Ray R. Evaluation of synergism between the aminogly-coside antibiotic streptomycin and the cardiovascular agent amlodipine. Biol Pharm Bull 2004; 27 (7): 1116–1120.
   PubMed Web of Science ®Google Scholar
• Blickle JF. Management of hypertension in elderly diabetic patients. Diabetes Metab 2005; 31 (2): 5S82–5S91.
   Google Scholar
• Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Mi-crobiol 2007; 45 (9): 2819–2828.
   PubMed Web of Science ®Google Scholar
• Akiyama S, Gottesman MM, Hanover JA, Fitzgerald DJ, Willingham MC, Pastan I. Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exo-toxin and antitransferrin receptor with Pseudomonas exotoxin. J Cell Physiol 1984; 120 (3): 271–279.
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Mantengoli E. Treatment and control of se-vere infections caused by multiresistant Pseudomonas aerugi-nosa. Clin Microbiol Infect 2005; 11 Suppl 4: 17–32.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade: Multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus Spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol, 2007; 1010 (5): 436-440.
   Google Scholar
• Birkenhäger WH, Staessen JA. Progress in cardiovascular diseases: Cognitive function in essential hypertension. Progr Car-diovasc Dis, 2006; 49 (1): 1–10.
   PubMed Web of Science ®Google Scholar
• Inzitari D, Poggesi A. Calcium channel blockers and stroke. Aging Clin Exp Res 2005; 17(4 Suppl): 16–30.
   PubMedGoogle Scholar
• Inzitari M, Di Bari M, Marchionni N. Calcium channel blockers and coronary heart disease. Aging Clin Exp Res 2005; 17(4 Suppl): 6–15.
   PubMedGoogle Scholar
• Pascual J. Hypertension control in the elderly with am-lodipine. Curr Med Res Opin 2000; 16 (1): 33–36.
   PubMed Web of Science ®Google Scholar
• Schulman IH, Zachariah M, Raij L. Calcium channel blockers: Endothelial dysfunction and combination therapy. Aging Clin Exp Res 2005; 17(Suppl 4): 40–45.
   PubMedGoogle Scholar
• Ungar A, Di Serio C, Lambertucci L, Monami M, Masotti G. Calcium channel blockers and nephroprotection. Aging Clin Exp Res 2005; 17(4 Suppl): 31–39.
   PubMedGoogle Scholar
• Viray M, Linkin D, Maslow JN, Stieritz DD, Carson LS, Bilker WB, et al. Longitudinal trends in antimicrobial susceptibil-ities across long-term-care facilities: Emergence of fluoro-quinolone resistance. Infect Control Hosp Epidemiol 2005; 26 (1): 56–62.
   PubMed Web of Science ®Google Scholar